Phase 1 study evaluating the safety, preliminary efficacy, and pharmacodynamics of recombinant interleukin-15 in combination with nivolumab and ipilimumab in patients with refractory cancers
Year: 2025
Type: article
Language: en
Topic: Immune Cell Function and Interaction
Authors and affiliations:
raw_author_name: Jibran Ahmed
raw_affiliation_strings: Center for Cancer Research, National Cancer Instiute, Bethesda, Maryland, USA
Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, Maryland, USA
raw_author_name: Geraldine O’Sullivan Coyne
raw_affiliation_strings: Center for Cancer Research, National Cancer Instiute, Bethesda, Maryland, USA
Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, Maryland, USA
raw_author_name: Larry V Rubinstein
raw_affiliation_strings: Biometric Research Program, National Cancer Institute Division of Cancer Treatment and Diagnosis, Bethesda, Maryland, USA
raw_author_name: Sarah J Shin
raw_affiliation_strings: Center for Cancer Research, National Cancer Instiute, Bethesda, Maryland, USA
Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, Maryland, USA
raw_author_name: Naoko Takebe
raw_affiliation_strings: Center for Cancer Research, National Cancer Instiute, Bethesda, Maryland, USA
Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, Maryland, USA
raw_author_name: Ashley Bruns
raw_affiliation_strings: Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, Maryland, USA
raw_author_name: Brooke Augustine
raw_affiliation_strings: Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, Maryland, USA
raw_author_name: Jessica Mukherjee
raw_affiliation_strings: Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, Maryland, USA
raw_author_name: Ning Ma
raw_affiliation_strings: Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, Maryland, USA
raw_author_name: Kristin Fino
raw_affiliation_strings: Clinical Pharmacodynamic Biomarkers Program, National Cancer Institute Frederick National Laboratory for Cancer Research, Frederick, Maryland, USA
raw_author_name: King Leung Fung
raw_affiliation_strings: Clinical Pharmacodynamic Biomarkers Program, National Cancer Institute Frederick National Laboratory for Cancer Research, Frederick, Maryland, USA
raw_author_name: Katherine V Ferry-Galow
raw_affiliation_strings: Clinical Pharmacodynamic Biomarkers Program, National Cancer Institute Frederick National Laboratory for Cancer Research, Frederick, Maryland, USA
raw_author_name: Barry C Johnson
raw_affiliation_strings: Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, Maryland, USA
raw_author_name: Ralph E Parchment
raw_affiliation_strings: Clinical Pharmacodynamic Biomarkers Program, National Cancer Institute Frederick National Laboratory for Cancer Research, Frederick, Maryland, USA
raw_author_name: Howard Streicher
raw_affiliation_strings: National Cancer Institute Cancer Therapy Evaluation Program, Bethesda, Maryland, USA
raw_author_name: James H Doroshow
raw_affiliation_strings: Center for Cancer Research, National Cancer Instiute, Bethesda, Maryland, USA
Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, Maryland, USA
raw_author_name: Alice P Chen
raw_affiliation_strings: Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, Maryland, USA